3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
43
Neoplasm Metastasis
5
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Brain Neoplasms
3
Stomach Neoplasms
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
HER2-positive Breast Cancer
2
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Thrombocytosis
1
Sarcoma
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pathologic Complete Response
1
Ovarian Neoplasms
1
Neoplasm, Residual
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Metastatic HER2-positive Breast Cancer With Brain Metastasis
1
Lymphoma, Non-Hodgkin
1
Lung Neoplasms
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic-Phase
1
Interventions
atezolizumab
1
alectinib
1
Vemurafenib
1
Neoadjuvant Therapy
1
Fruit
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Genomic Instability
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT02314481
2026-05-04
DARWINII
University College, London
Phase 2
Completed
50 enrolled